Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer

Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Kathryn E. Falberg has been appointed Senior Vice President and Chief Financial Officer. Ms. Falberg brings to Jazz Pharmaceuticals more than 20 years of financial officer and director experience. As Jazz Pharmaceutical's CFO, Ms. Falberg will be responsible for the Company's accounting, corporate finance, financial planning, investor relations, and treasury functions.


Ms. Falberg joins Jazz Pharmaceuticals from ARCA biopharma, where she served as CFO and Chief Operating Officer. From 2001 until joining ARCA in 2009, Ms. Falberg worked as an active investor and consultant to small companies and served as a corporate director/audit committee chair for several companies. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and CFO, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg currently serves on the Boards of Directors for ESS Technology, Halozyme Therapeutics and QLT. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a CPA.


About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.

 

SOURCE Jazz Pharmaceuticals, Inc.
Willie Quinn, Executive Director, Corporate Development of Jazz Pharmaceuticals, Inc., [email protected]
 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.